Core Viewpoint - The investor webinar focuses on Xenon Pharmaceuticals' Kv7 and Nav1.7 programs aimed at pain treatment, highlighting the company's leadership in ion channel drug development [1][4]. Company Overview - Ian Mortimer serves as the President and CEO of Xenon Pharmaceuticals and is moderating the session [1]. - The company has a strong pipeline and a history of positioning itself as a leader in ion channel drug development [4]. Key Personnel - Dr. Jim Empfield, Executive Vice President of Drug Discovery, will discuss Xenon's history and its advancements in drug development [3][4]. - Dr. JP Gilbert, Senior Director of Biology, and Dr. Chris Kenney, Chief Medical Officer, are also part of the speaking team [3].

Core Insights - Xenon Pharmaceuticals Inc. is hosting an investor webinar on October 6, 2025, to discuss its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain [1][2]. Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company engaged in drug discovery, clinical development, and commercialization of therapeutics for patients in need [4]. - The company's lead molecule, azetukalner, is a selective Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [4]. - Xenon is also advancing a portfolio of potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for pain treatment [4]. Webinar Details - The webinar will take place from 11:30 AM to 12:30 PM Eastern Time, and participants can submit questions via chat or email [2]. - A live webcast will be available on the "Investors" section of Xenon's website, with a replay posted after the event [3].